Fuse Diagnostics is focused on delivering laboratory-quality diagnostic information wherever it is needed through innovative, rapid, low-cost tests – addressing the cost and performance challenges of established approaches. The company is developing a revolutionary new generation of multianalytic diagnostic products, based on its Flip and Apex platforms, to make accurate point-of-need testing a reality for all. Fuse founders Harry and Ralph Lamble previously founded Sense Biodetection where they developed the world's first rapid instrument-free, molecular diagnostic test (Veros COVID-19) during the pandemic. Following the acquisition of Sense by Sherlock Biosciences in 2023, the brothers decided to apply their experience of clinical product development and commercialisation to address the widespread demand for rapid onsite pathogen testing across industry.